Odd Lots
Moderna's CFO on How to Allocate Capital in Big Pharma
Mar 11, 2024
Jamey Mock, Chief Financial Officer of Moderna, shares his insights on capital allocation in the unpredictable world of pharmaceuticals. He discusses how the lengthy drug development process complicates investment decisions. The impact of government funding during the pandemic on corporate strategy is explored, as is the importance of balancing long-term innovation with immediate market demands. Jamey also touches on the financial dynamics following Moderna's successful COVID vaccine, highlighting their considerable cash reserves and future investment plans.
48:25
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- In the pharmaceutical industry, decision-making on capital allocation is complex due to uncertainties in drug development, market size, and regulatory changes.
- Moderna focuses on strategic capital allocation for research and development, stakeholder management, and financial oversight to drive growth.
Deep dives
Moderna's Business Overview
Moderna, a company specializing in mRNA technology, is focused on developing various drug candidates for infectious diseases, cancer therapy, rare diseases, and respiratory diseases. They have a robust pipeline of 45 drug candidates and are known for their groundbreaking work during the COVID-19 pandemic. Moderna's technology revolves around mRNA that helps produce proteins in the body to combat diseases. With a strong focus on research and development, they aim to address various therapeutic areas like oncology, rare diseases, and respiratory diseases.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
